Name: UMIN ID:
Unique ID issued by UMIN | UMIN000030359 |
---|---|
Receipt number | R000034631 |
Scientific Title | Phase II trial of eribulin in patients with recurrent glioblastoma (ENIGMA) |
Date of disclosure of the study information | 2017/12/19 |
Last modified on | 2021/10/13 15:34:13 |
No. | Disposal | Last modified on | Item of update | |
---|---|---|---|---|
1 | Insert | 2017/12/12 10:21:52 | ||
2 | Update | 2017/12/12 10:25:16 | Last name of contact person Last name of contact person Division name Division name Date of disclosure of the study information |
|
3 | Update | 2017/12/12 10:59:43 | Last name of contact person Last name of contact person Division name Division name |
|
4 | Update | 2017/12/15 10:16:17 | UMIN ID1 UMIN ID2 |
|
5 | Update | 2017/12/15 10:19:15 | Date of disclosure of the study information |
|
6 | Update | 2017/12/19 19:35:12 | Name of secondary funder(s) Name of secondary funder(s) |
|
7 | Update | 2017/12/19 20:39:55 | Trial characteristics_1 |
|
8 | Update | 2018/01/20 09:59:38 | Recruitment status |
|
9 | Update | 2018/06/12 09:12:42 | Institutions |
|
10 | Update | 2019/06/14 22:39:27 | UMIN ID1 |
|
11 | Update | 2019/12/16 09:42:20 | 1st name of lead principal investigator Last name of lead principal investigator 1st name of lead principal investigator Last name of lead principal investigator Zip code Last name of contact person Last name of contact person Zip code Organization Organization Address Address Tel |
|
12 | Update | 2019/12/16 09:45:38 | Date of IRB Last follow-up date |
|
13 | Update | 2020/03/16 09:24:52 | UMIN ID1 |
|
14 | Update | 2020/04/30 14:57:05 | Recruitment status |
|
15 | Update | 2020/06/16 13:55:01 | Institutions |
|
16 | Update | 2021/10/08 13:29:39 | Recruitment status |
|
17 | Update | 2021/10/08 13:31:03 | Number of participants that the trial has enrolled |
|
18 | Update | 2021/10/08 13:47:59 | Email Organization1 |
|
19 | Update | 2021/10/13 15:34:13 | Email1 |